VRN110755 Phase 1/2 Clinical Trial Amendment Filed and Australian HREC Submission Completed... Global Expansion Underway, Neutral Impact on Shareholder Value
Voronoi submitted a clinical trial plan amendment for VRN110755 (EGFR-mutant NSCLC) to Taiwan TFDA on 2026-02-06, and completed submission to Australia HREC on 2026-05-26.
Based on safety, tolerability, and early efficacy signals from Phase 1a, the trial is expanding to Phase 1b/2 to evaluate optimal dose and efficacy.
Target enrollment is 391 patients across global sites in North America, Asia, Oceania, and Europe; trial duration up to 6 years including long-term follow-up.
Approval authorities include Taiwan TFDA and Australia HREC; additional amendment filings planned for Korea, Hong Kong, and Australia.
Risk note: Statistical probability of final drug approval is approximately 10%; commercialization plans may change or be abandoned based on clinical results.
[AI Comprehensive Analysis]This disclosure updates the administrative progress of VRN110755's clinical expansion and global entry, with no immediate positive or negative impact on enterprise value. However, clinical success remains a key driver for future stock price, and investors should monitor clinical risks continuously.
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related To Investment Decision (Application For Approval Of Clinical Trial Plan Change) (Phase 1/2 Clinical Trial Of VRN110755)